This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

SOHO 2026 Annual Meeting

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Topics Sessions Videos Previous meetings

Posters by Session

Select Session

$Thumbnail for Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Baseline Renal Impairment Treated With at Least 2 Prior Lines of Therapy in the DREAMM-7 Trial$

MM - 1135

Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Baseline Renal Impairment Treated With at Least 2 Prior Lines of Therapy in the DREAMM-7 Trial

Robert Rifkin

Poster Presenter: Robert Rifkin

Video

MM - 1145

Persistent Inequities in Multiple Myeloma Mortality Despite Therapeutic Advances in the United States

Baqir Jafry

Poster Presenter: Baqir Jafry

Previous 1...101 102 103 104 105 106 107...141 Next

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

Back

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Topics Sessions Videos Previous meetings

Posters by Session

Select Session

$Thumbnail for Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Baseline Renal Impairment Treated With at Least 2 Prior Lines of Therapy in the DREAMM-7 Trial$

MM - 1135

Efficacy Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Baseline Renal Impairment Treated With at Least 2 Prior Lines of Therapy in the DREAMM-7 Trial

Robert Rifkin

Poster Presenter: Robert Rifkin

Video

MM - 1145

Persistent Inequities in Multiple Myeloma Mortality Despite Therapeutic Advances in the United States

Baqir Jafry

Poster Presenter: Baqir Jafry

Previous 1...101 102 103 104 105 106 107...141 Next

Thumbnail for Comparative Efficacy of Carfilzomib-Based Versus Bortezomib-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials

MM - 1151

Comparative Efficacy of Carfilzomib-Based Versus Bortezomib-Based Regimens in Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis of Randomized Trials

Vasu Malhotra

Poster Presenter: Vasu Malhotra

Thumbnail for AI-Assisted Simplification of Clinic Notes for Patients With Plasma Cell Dyscrasias and Myeloid Neoplasms to Improve Patient Understanding and Satisfaction: A Prospective Pilot Study

MM - 116

AI-Assisted Simplification of Clinic Notes for Patients With Plasma Cell Dyscrasias and Myeloid Neoplasms to Improve Patient Understanding and Satisfaction: A Prospective Pilot Study

Karun Neupane

Poster Presenter: Karun Neupane

$Thumbnail for Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial$

MM - 1168

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Robert Rifkin

Poster Presenter: Robert Rifkin

Video

Thumbnail for Novel Interventions for Gastrointestinal Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan for Autologous Stem Cell Transplantation: A Systematic Review

MM - 1169

Novel Interventions for Gastrointestinal Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan for Autologous Stem Cell Transplantation: A Systematic Review

Sharanya Tripathi

Poster Presenter: Sharanya Tripathi

$Thumbnail for Comparative Outcomes of CAR-T Versus Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma: A TriNetX Network Analysis$

MM - 1173

Comparative Outcomes of CAR-T Versus Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma: A TriNetX Network Analysis

Faiza Khan

Poster Presenter: Faiza Khan

$Thumbnail for Infectious Morbidity with Bispecific T Cell Engager Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Synthesis Revealing a Preventable Survival Gap$

MM - 1174

Infectious Morbidity with Bispecific T Cell Engager Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Synthesis Revealing a Preventable Survival Gap

Saloni Haldule

Poster Presenter: Saloni Haldule

MM - 1183

Disparities in ASCT and CAR-T Access in Multiple Myeloma: Evidence from Real-World Studies in the Era of Novel Therapies

Saloni Haldule

Poster Presenter: Saloni Haldule

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next